Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2

Conditions

Glioma 12Glioblastoma 6Brain Neoplasms 4Neuroblastoma 3Recurrence 2Parkinson Disease 2Oligodendroglioma 2Neuroendocrine Tumors 2Gliosarcoma 2Ependymoma 2Congenital Hyperinsulinism 2Astrocytoma 2Thyroid cancer, medullary 1Pheochromocytoma 1Parkinsonian Disorders 1Paraganglioma 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Lewy Body Disease 1Insulinoma 1Glioma, Subependymal 1Carcinoid Tumor 1

Interventions

fluorodopa F 18 2Positron Emission Tomography Computed Tomography 1Neuropsychological Tests 1Furosemide 1Clinical Laboratory Techniques 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease × fluorodopa F 18 × CNS × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡